Vimal Mehta | Founder & CEO |
Richard Steinhart | SVP & CFO |
Matt Wiley | SVP & Chief Commercial Officer |
Robert Risinger | Chief Medical Officer, Neuroscience |
Frank Yocca | Chief Scientific Officer |
Gregory Harrison | Bank of America |
Colin Bristow | UBS |
Sumant Kulkarni | Canaccord |
Raghuram Selvaraju | H.C. Wainwright |
Yatin Suneja | Guggenheim Securities |
Samir Devani | Rx Securities |
Kambiz Yazdi | Jefferies |
Good morning, and welcome to BioXcel Therapeutics' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company.